In December 2007, the Thai Trade Competition Commission found that Abbott’s withdrawal of drug registration applications did not constitute a violation of the Thai Trade Competition Act. According to Thai health officials, the grant of the compulsory license on Efavirenz has resulted in important price decreases for the patented medicine, from 58 baht/month (price of the patented drug before the compulsory license was granted) to 24 baht/month (price of the patented drug after the compulsory license was granted). The compulsory license also enabled the introduction of a generic version of Efavirenz, at only 7.5 baht/month.421 The patent holders receive a remuneration of 0.5 per cent of the total sales value of the generic copies.